Market Place
Sourcing Support
AMGEN Presents Phase 3 Data For UPLIZNA® In Generalized Myasthenia
15 Oct 2024 //
PR NEWSWIRE
Amgen`s drug meets main goal in late-stage study for rare disease
06 Jun 2024 //
REUTERS
Amgen: Positive Uplizna Phase 3 Trial In Immunoglobulin G4-Related Disease
05 Jun 2024 //
PR NEWSWIRE
Horizon Therapeutics plc Announces New UPLIZNA Data
02 Oct 2023 //
BUSINESSWIRE
New Analysis of MRI Shows UPLIZNA Reduced Formation of Spinal Cord Lesions
30 Jun 2023 //
BUSINESSWIRE
UPLIZNA Pivotal Trial Publication Shows Accuracy of Attack Diagnoses for NMOSD
12 Jun 2023 //
BUSINESSWIRE
Biomarker Analysis Publication Illustrates Efficacy of UPLIZNA
01 Jun 2023 //
BUSINESSWIRE
Analysis of MRI Findings Show UPLIZNA Reduced the Formation of Asymptomatic Optic Nerve Lesions
14 Mar 2023 //
BUSINESSWIRE
UPLIZNA® (inebilizumab-cdon) Approved in Brazil for the Treatment of NMOSD
20 Dec 2022 //
PRESS RELEASE
UPLIZNA® (inebilizumab-cdon) Approved in Brazil for NMOSD
20 Dec 2022 //
BUSINESSWIRE
Horizon`s Uplizna Receives Approval in Europe
30 Nov 2022 //
EMA
New Analysis of UPLIZNA® (inebilizumab-cdon) Phase 3 Trial Data Demonstrates
26 Oct 2022 //
PRESS RELEASE
Horizon Therapeutics Announces UPLIZNA NMOSD to be presented at ECTRIMS 2022
12 Oct 2022 //
BUSINESSWIRE
New Analysis Finds UPLIZNA Effective Among European Populations with NMOSD
24 Jun 2022 //
BUSINESSWIRE
Horizon Tx Submits Regulatory Filing for UPLIZNA in Brazil
15 Jun 2022 //
BUSINESSWIRE
Analysis from PIII N-MOmentum Study Demonstrates the Effectiveness of UPLIZNA
31 May 2022 //
BUSINESSWIRE
Viela Bio Biologic Uplizna (Inebilizumab) Receives Approval in Europe
19 May 2022 //
EMA
Horizon Bags EC Approval of UPLIZNA for Neuromyelitis Optica Spectrum Disorder
02 May 2022 //
BUSINESSWIRE
New Analysis Finds UPLIZNA Effective in Neuromyelitis Optica Spectrum Disorder
31 Mar 2022 //
BUSINESSWIRE
Study Analysis: UPLIZNA Reduces Severity of Attacks Associated with NMOSD
16 Feb 2022 //
BUSINESSWIRE
New Data Builds Relationship Among B-Cell Depletion & Improved Result of UPLIZNA
13 Oct 2021 //
BUSINESSWIRE
Inebilizumab has been approved in South Korea
05 Aug 2021 //
FIRSTWORDPHARMA
New Analysis of UPLIZNA® (inebilizumab-cdon) for (NMOSD)
06 May 2021 //
YAHOO
UPLIZNA® (inebilizumab-cdon) Approved by Japanese Ministry of Health
24 Mar 2021 //
BUSINESSWIRE
Viela Bio`s Uplizna (Inebilizumab ) Receives Supplemental Approval in US
13 Jun 2020 //
FDA
PANTHERx® Chosen as Exclusive Rare Pharmacy Partner by Viela Bio for Uplizna™
12 Jun 2020 //
PRNEWSWIRE
Viela Bio Announces U.S. FDA Approval of UPLIZNA™ (inebilizumab-cdon)
11 Jun 2020 //
GLOBENEWSWIRE
FDA Approves New Therapy for Rare Disease Affecting Optic Nerve, Spinal Cord
11 Jun 2020 //
PRNEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.